HCPLive Network


HDL cholesterol may have atheroprotective qualities, according to a report from The New England Journal of Medicine.
Can cholesterol get too low? Results from a multicenter international study called IMPROVE-IT show that adding ezetimibe to a statin regimen lowered cholesterol without harmful side effects in patients with acute coronary syndrome.
Physicians caring for individuals with chronic kidney disease (CKD) must strike a balance between ensuring optimal lipid control for protection from vascular events, while avoiding undue risk.
Despite achieving optimal goals for “bad” cholesterol levels, individuals with diabetes and chronic kidney disease still have an elevated risk of vascular complications.
High-intensity statin therapy is associated with coronary atherosclerosis regression, regardless of baseline lipoprotein or C-reactive protein levels, according to a study published in the Nov. 15 issue of The American Journal of Cardiology.
Homozygous familial hypercholesterolemia (HoFH) is a rare and severe hereditary lipid disorder. Patients with HoFH generally have very high serum levels of low-density lipoprotein cholesterol (LDL-C) that is treatment-resistant. HoFH puts affected patients at extremely high risk of premature onset coronary heart disease, and many patients die before they reach their mid-30s.
Atherosclerosis Upcoming Events
Ventura, California
February 9-14, 2014
Paris, France
February 27 – March 1, 2014
San Diego, California
March 4-7, 2014
Madrid, Spain
May 31 – June 3, 2014
Boston, MA
July 25-28, 2015
Cambridge, England, United Kingdom
September 25-26, 2014
Washington DC
February 21-24, 2015
Amsterdam, The Netherlands
May 24-27, 2015
Newry, ME
June 21-26, 2015
Nashville, TN
February 11-13, 2015
Atherosclerosis Latest News
Atherosclerosis Clinical Trials
Atherosclerosis Resources